JNJ.DE Johnson & Johnson
Company Analysis
Latest News
🟢 JNJ.DE climbs 3.7% on MedTech launch and pharma pipeline strength
JNJ.DE is trading 3.7% up at $218.60, fueled by the commercial launch of its Dual Energy THERMOCOOL SMARTTOUCH SF Platform in Europe today. The rally is...
🟢 JNJ.DE is trading 0.9% up today amid positive clinical data and increased institutional interest
• Johnson & Johnson has seen positive mid-June clinical and product updates, including strong TALVEY combination data in multiple myeloma and positive Phase...
Johnson & Johnson TRUFILL cuts brain bleed recurrence risk by 47%
Johnson & Johnson published primary results from the MEMBRANE randomized controlled trial in JAMA Neurology on June 19, 2026. The study evaluated middle...
Johnson & Johnson invests $1B in Florida, scaling ACUVUE contact lens production
Johnson & Johnson is investing over $1 billion to expand its vision care operations in Jacksonville, Florida. The project scales domestic manufacturing and...
Johnson & Johnson’s TALVEY Beats Standard Care in Multiple Myeloma Trial
Johnson & Johnson announced Phase 3 MonumenTAL-3 study results for its multiple myeloma therapy at the 2026 European Hematology Association (EHA) Annual...
Johnson & Johnson's Anemia Drug IMAAVY Shows Positive Results in Late-Stage Trial
Johnson & Johnson announced positive results from a pivotal Phase 2/3 study of its drug, IMAAVY (nipocalimab), for warm autoimmune hemolytic anemia (wAIHA)....